Literature DB >> 8943377

Regulation of surface and intracellular expression of CTLA4 on mouse T cells.

M L Alegre1, P J Noel, B J Eisfelder, E Chuang, M R Clark, S L Reiner, C B Thompson.   

Abstract

CTLA4 is a cell surface molecule that shares 30% homology with CD28 and binds B7 family members with high affinity. Analysis of surface expression on murine T cells revealed up-regulation after stimulation with anti-CD3 mAb in vitro and further augmentation after the addition of exogenous IL-2 or anti-CD28 mAb. The effects of IL-2 and anti-CD28 mAb were additive and in part independent, as anti-CD28 mAb increased anti-CD3 mAb-induced T cell CTLA4 expression in IL-2-deficient mice. In contrast, CTLA4 expression was only minimally augmented by the addition of IL-4, IL-6, IL-7, or IL-12. Expression of CTLA4 induced by anti-CD3 mAb was inhibited by anti-IL-2 plus anti-IL-2R mAbs. Inasmuch as these agents prevented T cell proliferation, the effects of cell cycle inhibitors also were examined. Drugs blocking at G1 (cyclosporin A, mimosine) or S (hydroxyurea) phase inhibited the up-regulation of CTLA4 induced by anti-CD3 mAb, suggesting that entry into the cell cycle was necessary to increase the expression of CTLA4. The kinetics of intracellular expression of CTLA4 after stimulation with anti-CD3 mAb paralleled those of surface expression, but surprisingly, much more CTLA4 was localized in the cytoplasm of T lymphocytes than on the cell surface at each time point. Importantly, surface CTLA4 was rapidly internalized intracellularly, which may explain the low levels of expression generally detected on the cell surface. We conclude that both CD28 and IL-2 play important roles in the up-regulation of CTLA4 expression. In addition, the cell surface accumulation of CTL4 appears to be primarily regulated by its rapid endocytosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943377

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  93 in total

Review 1.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 2.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 3.  Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.

Authors:  Michael Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

4.  Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein.

Authors:  Y Zhang; J P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

5.  Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy.

Authors:  Yu Jin Lim; Jaemoon Koh; Kyubo Kim; Eui Kyu Chie; Sehui Kim; Kyoung Bun Lee; Jin-Young Jang; Sun Whe Kim; Do-Youn Oh; Yung-Jue Bang
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

6.  Foxp1 Negatively Regulates T Follicular Helper Cell Differentiation and Germinal Center Responses by Controlling Cell Migration and CTLA-4.

Authors:  Bi Shi; Jianlin Geng; Yin-Hu Wang; Hairong Wei; Beth Walters; Wei Li; Xuerui Luo; Anna Stevens; Melanie Pittman; Bin Li; Sunnie R Thompson; Hui Hu
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

7.  CD40L is transferred to antigen-presenting B cells during delivery of T-cell help.

Authors:  Jennifer L Gardell; David C Parker
Journal:  Eur J Immunol       Date:  2016-11-28       Impact factor: 5.532

8.  CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.

Authors:  Kavita V Shah; Andy J Chien; Cassian Yee; Randall T Moon
Journal:  J Invest Dermatol       Date:  2008-06-19       Impact factor: 8.551

9.  Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.

Authors:  Muhammad Khattak; Rosalie Fisher; Samra Turajlic; James Larkin
Journal:  Ther Adv Med Oncol       Date:  2013-03       Impact factor: 8.168

Review 10.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.